Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209351 · ClinicalTrials.gov registry record · Phase 1
Effect of Teduglutide on Gastric Emptying in Healthy Subjects
A Phase 1 study, sponsored by Shire.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01209351 is a Phase 1 study that has completed, run by Shire. The registered enrollment target is 36 participants.
The verdict
NCT01209351, a Phase 1 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the effects of 10 consecutive, daily, subcutaneous doses of 4 mg of teduglutide as compared with placebo on gastric emptying as assessed by acetaminophen absorption kinetics in healthy subjects.
Interventions
- DRUG Placebo
- DRUG teduglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2010-09-28 |
| Est. Completion | 2010-11-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01209351
The ClinicalTrials.gov registry entry for NCT01209351 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01209351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01209351 about?
NCT01209351 is a clinical study titled "Effect of Teduglutide on Gastric Emptying in Healthy Subjects". The primary objective of this study is to assess the effects of 10 consecutive, daily, subcutaneous doses of 4 mg of teduglutide as compared with placebo on gastric emptying as assessed by acetaminophen absorption kinetics in healthy subjects.
What is the current status of trial NCT01209351?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2010-09-28. Estimated completion is 2010-11-08.
What interventions are being tested in trial NCT01209351?
The interventions under investigation include: Placebo (DRUG), teduglutide (DRUG).
Who is sponsoring clinical trial NCT01209351?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.